Thermo Fisher Scientific (NYSE:TMO) Releases FY 2025 Earnings Guidance

Key Points

• Thermo Fisher Scientific has issued its FY 2025 earnings guidance, projecting earnings per share (EPS) of 22.600-22.860 and revenue of $44.1 billion-$44.5 billion, surpassing consensus estimates.
• The company reported quarterly earnings of $5.79 EPS, beating analysts' expectations, with a revenue of $11.12 billion for the period.
• Despite positive earnings, several analysts have adjusted their ratings on Thermo Fisher's stock, with 15 analysts rating it as a Buy and five as a Hold.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 22.600-22.860 for the period, compared to the consensus earnings per share estimate of 22.500. The company issued revenue guidance of $44.1 billion-$44.5 billion, compared to the consensus revenue estimate of $43.9 billion.

Thermo Fisher Scientific Price Performance

NYSE TMO traded up $2.67 on Wednesday, hitting $560.66. 589,553 shares of the company were exchanged, compared to its average volume of 2,407,106. The company has a market cap of $211.71 billion, a P/E ratio of 32.48, a P/E/G ratio of 3.14 and a beta of 0.77. The firm has a 50 day moving average of $499.00 and a two-hundred day moving average of $450.49. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. Thermo Fisher Scientific has a 1-year low of $385.46 and a 1-year high of $610.97.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, beating analysts' consensus estimates of $5.50 by $0.29. The business had revenue of $11.12 billion for the quarter, compared to the consensus estimate of $10.90 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. Thermo Fisher Scientific's revenue for the quarter was up 4.9% on a year-over-year basis. During the same period last year, the company posted $5.28 EPS. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, equities analysts predict that Thermo Fisher Scientific will post 23.28 EPS for the current year.

Analysts Set New Price Targets

TMO has been the subject of several research reports. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Thermo Fisher Scientific in a research note on Tuesday, October 14th. Wall Street Zen cut shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research note on Sunday, October 12th. Redburn Partners set a $580.00 target price on shares of Thermo Fisher Scientific in a research note on Wednesday, October 8th. Evercore ISI raised their target price on shares of Thermo Fisher Scientific from $525.00 to $590.00 and gave the company an "outperform" rating in a research note on Tuesday, October 7th. Finally, Scotiabank raised Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price target for the company in a report on Friday, July 11th. Fifteen equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $581.72.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $500.96, for a total value of $5,009,600.00. Following the transaction, the chief executive officer owned 115,174 shares in the company, valued at $57,697,567.04. The trade was a 7.99% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Gianluca Pettiti sold 400 shares of the business's stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the sale, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 30,066 shares of company stock worth $14,182,963 over the last 90 days. Insiders own 0.33% of the company's stock.

Institutional Trading of Thermo Fisher Scientific

Several institutional investors have recently added to or reduced their stakes in TMO. Corient Private Wealth LLC boosted its holdings in Thermo Fisher Scientific by 89.1% in the second quarter. Corient Private Wealth LLC now owns 1,752,607 shares of the medical research company's stock valued at $720,576,000 after acquiring an additional 825,649 shares during the last quarter. Unisphere Establishment boosted its holdings in Thermo Fisher Scientific by 5.6% in the second quarter. Unisphere Establishment now owns 2,060,000 shares of the medical research company's stock valued at $835,248,000 after acquiring an additional 110,000 shares during the last quarter. Glenview Capital Management LLC bought a new stake in Thermo Fisher Scientific in the second quarter valued at approximately $40,546,000. Route One Investment Company L.P. lifted its stake in Thermo Fisher Scientific by 26.2% in the second quarter. Route One Investment Company L.P. now owns 293,380 shares of the medical research company's stock valued at $118,954,000 after buying an additional 60,950 shares during the period. Finally, Raymond James Financial Inc. lifted its stake in Thermo Fisher Scientific by 7.4% in the second quarter. Raymond James Financial Inc. now owns 778,822 shares of the medical research company's stock valued at $315,781,000 after buying an additional 53,542 shares during the period. 89.23% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.